Overview

Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
0
Participant gender:
All
Summary
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in continuous ambulatory peritoneal dialysis (CAPD) who have received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. This study is also all case investigation of which the enrollment period is one year, and all patients in CAPD who received Fosrenol for hyperphosphatemia will be recruited and followed one year.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Criteria
Inclusion Criteria:

- Patients undergoing continuous ambulatory peritoneal dialysis who received Fosrenol
for hyperphosphatemia

Exclusion Criteria:

- Patients who are contraindicated based on the product label